1903008-80-9 lazertinib

Eignir

Útlit ljósgult til gult duft
Þéttleiki 1,27 ± 0,1 g/cm3
Storage Temp . Store á -20 gráðu
leysni DMSO: 6 . 5 (Max Conc. Mg/ml);

Umsókn:

Lazertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) primarily used to treat EGFR gene mutation positive non-small cell lung cancer (NSCLC) patients, particularly in late stage cases of EGFR T790M resistant or EGFR sensitive mutations (such as exon 19 deletion or L858R mutation). Lazertinib inhibits the abnormally activated EGFR merkjaslóð, hindrar æxlisfrumuvöxt og hefur gott skarpskyggni í miðtaugakerfi, sem getur dregið úr meinvörpum í heila .
 

Samheiti:

Lazertinib

1903008-80-9

Yh -25448

GNS -1480

2- própenamíð, N-(5- ((4- (4- ((dimethylamino) metýl) -3- fenýl -1 h-pyrazol {{8} } YL) -2- pyrimidinyl) amínó) -4- metoxy -2- (4- morpholinyl) fenýl)--

N-(5- ((4- (4- ((dimethylamino) metýl) -3- fenýl -1 h-pyrazol -1- yl) -2- pyrimidinyl) amínó) -4- metoxý -2- (4- morpholinyl) fenýl) akrýlamíð

maq per Qat: 1903008-80-9 lazertinib, Kína 1903008-80-9 Lazertinib Framleiðendur, birgjar